AI in Healthcare

Today's Stories

1. 1

   AWS publishes architectural patterns for multi-tenant AI agents, showing how to isolate customer data and enforce service tiers using native cloud capabilities.

   AWS published a blog post demonstrating how to build multi-tenant AI applications using Amazon Bedrock AgentCore, with a healthcare example that implements two service tiers—Basic (using Mistral Ministral 3 8B Instruct for small clinics) and Premium (using OpenAI GPT OSS 120B with web search for hospitals and specialty centers). Multi-tenant AI systems face real operational risks: customer data exposure, inconsistent service quality across pricing tiers, and hidden cost overruns. This post addresses those challenges by showing how to enforce complete tenant isolation through document scoping, memory separation, model access control, and granular cost attribution—all without building custom isolation infrastructure.

   The solution uses a pool model where tenants share underlying compute resources (rather than dedicated silos), maximizing efficiency while maintaining logical isolation through scoped identifiers, access policies, and data partitioning. Sample code is available on GitHub at https://github.com/aws-samples/sample-agentcore-and-multitenancy-blog.

2. 2

   Insilico Medicine and SK Biopharmaceuticals are partnering on a $2.5 billion（約4000億円） AI drug discovery effort focused on neuroimmune therapies, marking a major bet by a major pharmaceutical company on AI-driven drug development.

   Insilico Medicine, an AI drug discovery company, and SK Biopharmaceuticals have struck a deal valued at $2.5 billion（約4000億円） to discover and develop new therapies in neuroimmune diseases using AI technology. This partnership represents a significant validation of AI-powered drug discovery by an established pharmaceutical player. SK Biopharmaceuticals' backing signals that major drugmakers now see AI as a viable path to identify and develop medicines, moving beyond pure research partnerships into concrete financial commitments.

   The deal targets neuroimmune therapies specifically, a therapeutic area where both companies aim to apply Insilico's AI platform to accelerate the traditionally slow and costly drug development process.

3. 3

   Thermo Fisher Scientific is showcasing new AI-enabled research capabilities and expanded manufacturing services at BIO International 2026, signaling the company's push to integrate artificial intelligence into life sciences workflows.

   Thermo Fisher Scientific unveiled new capabilities across manufacturing, clinical development, and AI-enabled research at BIO International 2026. The company is highlighting tools and services designed to support biotech and pharmaceutical customers across these areas. Life sciences companies increasingly rely on manufacturing partners and research tools to accelerate development timelines. Thermo Fisher's expanded suite—especially AI-enabled research capabilities—addresses customer demand for faster, more efficient workflows in a competitive drug development environment.

   The company is presenting these capabilities at BIO International 2026, a major industry conference. Customers and competitors will be watching to see how Thermo Fisher's AI tools integrate into existing research and manufacturing processes, and whether they deliver meaningful time or cost savings in practice.

4. 4

   Thermo Fisher Scientific is expanding AI-enabled research tools, advanced manufacturing capacity, and clinical development capabilities to help pharma and biotech customers accelerate drug development and bring therapies to market faster.

   Thermo Fisher announced new investments across three areas at BIO International 2026. On manufacturing, the company is expanding sterile fill-finish and device assembly capacity (including a collaboration with SHL Medical at its Ridgefield, New Jersey site), launching new GMP monoclonal antibody manufacturing capabilities in Plainville, Massachusetts in the second half of 2026, and adding biologics drug substance capacity in the U.S. and Switzerland. On research, Thermo Fisher is introducing AI-enabled analytics and clinical research capabilities through Clario and forming strategic partnerships with NVIDIA, OpenAI, TetraScience, and BenchSci to help customers automate laboratory workflows and unify scientific data. Pharma and biotech companies are under pressure to reduce development timelines and are increasingly seeking data-driven, connected approaches across research, clinical testing, and manufacturing. Thermo Fisher positions itself as a single integrated provider that can help customers simplify complex workflows across the entire drug development lifecycle—from discovery through commercialization.

   The company is launching new GMP monoclonal antibody manufacturing in Plainville, Massachusetts in the second half of 2026, and expanding its Bioprocess Design Center network with new facilities in the U.S. and India to provide local expertise and collaborative environments for customers scaling up manufacturing.

5. 5

   Jacobi–IDE, a development tool for Abaqus subroutines, now runs analytical physics tests automatically and can send failed diagnostics to Claude for AI-powered debugging.

   Jacobi–IDE compiles and runs a suite of 12 physics tests on Abaqus subroutines (specialist engineering simulation code), flagging errors in material properties, yield behavior, and numerical stability. When tests fail, the tool sends diagnostic data to Claude, an AI assistant, which suggests the likely cause—such as a volumetric component in plastic flow that needs correction. Writing and validating Abaqus subroutines is error-prone and time-consuming; engineers typically must debug by hand. Automated analytical tests catch physical inconsistencies early, and AI diagnosis narrows the search space for fixes, reducing iteration cycles and the expertise barrier for less experienced developers.

   The tool is demonstrated passing 10 of 12 tests on an elastic–plastic material model, with Claude correctly identifying a suspected issue in the failed cases. Availability, pricing, and compatibility with different Abaqus versions are not stated in the announcement.

6. 6

   Eli Lilly and Twist Bioscience are pursuing separate AI-driven paths to drug discovery, signaling how companies are industrializing machine learning in biopharma.

   Eli Lilly has partnered with Nvidia and built an internal AI platform to accelerate drug discovery, while Twist Bioscience is taking a vendor-agnostic approach, developing AI tools for synthetic biology and enabling customers to build their own discovery workflows. AI is moving from research proof-of-concept into production use in pharmaceuticals—a sector where development cycles and regulatory stakes are extremely high. The two companies' contrasting strategies reflect a broader question in biopharma: whether to centralize AI infrastructure and expertise in-house (like Eli Lilly) or to democratize tools so partners can run their own workflows (like Twist Bioscience).

   Both firms are integrating AI into their core discovery pipelines now, not in the distant future. The success of either approach will likely influence how other large pharma and biotech companies decide to invest in and deploy AI for drug development over the next few years.